How many drugs treat Prevention of Motion Sickness?

Drug Landscape tracks 4 marketed treatments for Prevention of Motion Sickness (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/prevention-of-motion-sickness.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prevention of Motion Sickness — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Motion Sickness (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of Motion Sickness, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Dimenhydrinate	DIMENHYDRINATE	Alra	dimenhydrinate	Histamine H1 receptor	1972-01-01
Antivert	meclizine	Generic (originally Pfizer/UCB)	Antihistamine/Antiemetic (vestibular suppressant)	Nuclear receptor subfamily 1 group I member 3, Serine protease hepsin, Histamine H1 receptor	1957-01-01
Antivert	meclozine	Citron Pharma Llc	Antiemetic	Nuclear receptor subfamily 1 group I member 3	1957-01-01
scopolamin	scopolamin	University Hospital, Angers		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Alra · 1 drug in Prevention of Motion Sickness
Citron Pharma Llc · 1 drug in Prevention of Motion Sickness
Generic (originally Pfizer/UCB) · 1 drug in Prevention of Motion Sickness
University Hospital, Angers · 1 drug in Prevention of Motion Sickness

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of Motion Sickness:

Cite this brief

Drug Landscape (2026). Prevention of Motion Sickness — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-motion-sickness. Accessed 2026-06-10.

Prevention of Motion Sickness full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing